Literature DB >> 22614188

Parathyroid scintigraphy: when, how, and why? A concise systematic review.

David Taieb1, Elif Hindie, Gaia Grassetto, Patrick M Colletti, Domenico Rubello.   

Abstract

In recent years, preoperative imaging has become essential in the evaluation of sporadic primary hyperparathyroidism (HPT) for selecting good candidates for minimally invasive HPT. Its role in patients with secondary/tertiary HPT is under investigation. Imaging is mandatory before reoperative parathyroid surgery for persistent or recurrent HPT, whatever the setting. This review provides detailed information regarding the nuclear imaging methods (dual phase, subtraction), the role of SPECT and SPECT/CT, and the clinical results of parathyroid scintigraphy in different clinical situations.

Entities:  

Mesh：

Year:  2012        PMID： 22614188     DOI： 10.1097/RLU.0b013e318251e408

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN： 0363-9762            Impact factor:   7.794


  10 in total

1.  ¹⁸F-Fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study.

Authors:  Luka Lezaic; Sebastijan Rep; Mojca Jensterle Sever; Tomaz Kocjan; Marko Hocevar; Jure Fettich
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-26       Impact factor: 9.236

2.  Incremental value of CT in the localization of parathyroid adenomas.

Authors:  Feng Xu; Behram Pastakia; Frank Liu
Journal:  Radiol Case Rep       Date:  2015-12-03

3.  Non-visualized Thyroid Gland by Tc-99m MIBI Scan with Normal Thyroid Scan.

Authors:  Gokhan Koca; Hasan Ikbal Atilgan; Aylin Baskin; Koray Demirel; Meliha Korkmaz
Journal:  Nucl Med Mol Imaging       Date:  2013-04-10

4.  Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of 18F-Fluorocholine PET/CT.

Authors:  Serena Grimaldi; Jacques Young; Peter Kamenicky; Dana Hartl; Marie Terroir; Sophie Leboulleux; Amandine Berdelou; Julien Hadoux; Segolene Hescot; Hervé Remy; Eric Baudin; Martin Schlumberger; Désirée Deandreis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-22       Impact factor: 9.236

Review 5.  Diagnostic Value of Choline PET in the Preoperative Localization of Hyperfunctioning Parathyroid Gland(s): A Comprehensive Overview.

Authors:  Cristina Ferrari; Giulia Santo; Paolo Mammucci; Antonio Rosario Pisani; Angela Sardaro; Giuseppe Rubini
Journal:  Biomedicines       Date:  2021-02-25

6.  Comparison of five parathyroid scintigraphic protocols.

Authors:  Virpi Tunninen; Pekka Varjo; Jukka Schildt; Aapo Ahonen; Tomi Kauppinen; Irina Lisinen; Anu Holm; Hannu Eskola; Marko Seppänen
Journal:  Int J Mol Imaging       Date:  2013-01-21

7.  Sensitivity and Specificity of Dual-Isotope 99mTc-Tetrofosmin and 123I Sodium Iodide Single Photon Emission Computed Tomography (SPECT) in Hyperparathyroidism.

Authors:  Michael Sommerauer; Carmen Graf; Niklaus Schäfer; Gerhard Huber; Paul Schneider; Rudolf Wüthrich; Christoph Schmid; Hans Steinert
Journal:  PLoS One       Date:  2015-06-16       Impact factor: 3.240

8.  99mTc-Sestamibi/123I Subtraction SPECT/CT in Parathyroid Scintigraphy: Is Additional Pinhole Imaging Useful?

Authors:  Virpi Tunninen; Pekka Varjo; Tomi Kauppinen; Anu Holm; Hannu Eskola; Marko Seppänen
Journal:  Int J Mol Imaging       Date:  2017-10-18

9.  18F-Fluorocholine PET/CT in the assessment of primary hyperparathyroidism compared with 99mTc-MIBI or 99mTc-tetrofosmin SPECT/CT: a prospective dual-centre study in 100 patients.

Authors:  Mohsen Beheshti; Lukas Hehenwarter; Zeinab Paymani; Gundula Rendl; Larisa Imamovic; Rupert Rettenbacher; Oleksiy Tsybrovskyy; Werner Langsteger; Christian Pirich
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03-08       Impact factor: 9.236

10.  Unusual recurrent renal secondary hyperparathyroidism caused by hyperplastic autograft with supernumerary parathyroid adenoma: A case report.

Authors:  Jun Zhang; Meng-Jie Dong; Jun Yang; Dan Tian
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.